Commerce Bank Buys New Position in Zimmer Biomet Holdings, Inc. $ZBH

Commerce Bank purchased a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 12,935 shares of the medical equipment provider’s stock, valued at approximately $1,114,000.

Several other large investors have also added to or reduced their stakes in ZBH. BlackRock Inc. bought a new position in Zimmer Biomet in the 2nd quarter worth $1,344,282,000. Norges Bank bought a new stake in shares of Zimmer Biomet during the 4th quarter valued at about $221,234,000. Franklin Resources Inc. boosted its stake in shares of Zimmer Biomet by 43.2% during the 4th quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock valued at $601,204,000 after purchasing an additional 2,017,857 shares in the last quarter. Auto Owners Insurance Co increased its position in shares of Zimmer Biomet by 8,892.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,009,712 shares of the medical equipment provider’s stock valued at $180,713,000 after buying an additional 1,987,362 shares during the period. Finally, Equity Investment Corp purchased a new position in shares of Zimmer Biomet during the second quarter valued at about $144,748,000. Institutional investors own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on ZBH shares. Canaccord Genuity Group raised their price objective on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a report on Monday, August 10th. Zacks Research downgraded Zimmer Biomet from a “hold” rating to a “strong sell” rating in a report on Monday, July 27th. UBS Group reissued a “buy” rating and issued a $120.00 target price on shares of Zimmer Biomet in a research report on Thursday, August 6th. Citizens Jmp lowered their target price on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a research note on Wednesday, April 29th. Finally, Citigroup reduced their price target on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a research note on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $104.42.

Insider Activity at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the sale, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.28% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of ZBH opened at $101.41 on Thursday. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. The business’s 50 day moving average price is $93.40 and its 200-day moving average price is $91.31. Zimmer Biomet Holdings, Inc. has a 52 week low of $79.12 and a 52 week high of $107.85. The stock has a market cap of $19.34 billion, a P/E ratio of 24.67, a P/E/G ratio of 2.72 and a beta of 0.45.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The company had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.13 billion. During the same quarter in the prior year, the business posted $2.07 EPS. The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current fiscal year.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.